



High-Risk COVID-19 Patients May Avoid Hospitalization with Monoclonal Antibody Treatment

Is My Patient Eligible?

Your patient may be eligible for treatment with monoclonal antibodies if they have experienced the onset of mild to moderate symptoms of COVID-19 in the last 10 days, have tested positive for COVID-19, and have one or more of the following high-risk factors¹:

- **Are ≥65 years of age**
- **Body mass index (BMI) ≥35**
- **Chronic kidney disease**
- **Diabetes**
- **Immunosuppressive disease**
- **Are currently receiving immunosuppressive treatment**
- **Are ≥55 years of age AND have**
 - cardiovascular disease, OR
 - hypertension, OR
 - chronic obstructive pulmonary disease/other chronic respiratory disease
- **Are 12 to 17 years of age AND have**
 - BMI ≥85th percentile for their age and gender based on CDC growth charts, OR
 - sickle cell disease, OR
 - congenital or acquired heart disease, OR
 - neurodevelopmental disorders, for example, cerebral palsy, OR
 - a medical-related technological dependence, for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19), OR
 - asthma, reactive airway, or other chronic respiratory disease that requires daily medication for control



Early Action Is Vital

Early testing, identification, and referral are vital to access to monoclonal antibody treatment. So, consider:

- Discussing monoclonal antibodies, the importance of reporting symptoms, and COVID-19 testing with your high-risk patients during routine care appointments
- Pre-identifying patients who may be eligible for monoclonal antibody treatment



High-Risk COVID-19 Patients May Avoid Hospitalization with Monoclonal Antibody Treatment

Your patient is **not** eligible for treatment if they:

- Are hospitalized due to COVID-19, OR
- Require oxygen therapy due to COVID-19, OR
- Require an increase in baseline oxygen flow rate due to COVID-19 for those on chronic oxygen therapy due to an underlying non-COVID-19 related comorbidity

How to Find Infusion Locations

You can find infusion locations in your area:

- by visiting <https://protect-public.hhs.gov/pages/therapeutics-distribution>, OR
- by calling **1-877-332-6585** for English, or **1-877-366-0310** for Spanish

Contact the infusion location(s) to learn their referral procedures and whether they are accepting new patients.

For more information, visit
CombatCOVID.hhs.gov

English: 1-877-332-6585 • Spanish: 1-877-366-0310



COMBATCOVID



References

1. FACT SHEETS FOR HEALTH CARE PROVIDERS EMERGENCY USE AUTHORIZATION (EUA) OF BAMLANIVIMAB AND ETESEVIMAB (revised March 18, 2021) and CASIRIVIMAB AND IMDEVIMAB
<https://www.fda.gov/media/145802/download>
<https://www.fda.gov/media/143892/download>